Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaust Limited ( (AU:NUZ) ) has provided an announcement.
Neurizon Therapeutics has secured a A$6.0 million cash rebate under the Australian Government’s R&D Tax Incentive program for FY2025, reflecting a 48.5% rebate on eligible domestic and overseas R&D activities, supported by an Advance & Overseas Finding that extends through FY2027. After repaying a previously arranged A$1.5 million R&D financing facility with Radium Capital, the company receives about A$4.35 million in net cash, which will be directed to fund its participation in the HEALEY ALS Platform Trial and support broader clinical development and commercialisation readiness for NUZ-001, reinforcing its non-dilutive funding strategy and strengthening its competitive position as an Australian-based neurodegenerative drug developer.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), with a strategy to accelerate patient access to effective ALS therapies while exploring broader applications of NUZ-001 across other neurodegenerative indications through international collaborations and rigorous clinical programs.
Average Trading Volume: 490,012
Technical Sentiment Signal: Sell
Current Market Cap: A$80.46M
For an in-depth examination of NUZ stock, go to TipRanks’ Overview page.